What Orum Therapeutics does

Orum Therapeutics is a clinical-stage biotechnology company developing degrader-antibody conjugates (DACs), a therapeutic modality that combines proprietary molecular glue degrader payloads (notably GSPT1 degraders such as SMol006) with tumor-targeting antibodies connected via β-glucuronide cleavable linkers. Its Dual-Precision Targeted Protein Degradation (TPD²) platform uses the E3 ubiquitin ligase pathway to selectively degrade intracellular oncoproteins in defined cell populations, addressing cancers that are difficult to treat with conventional modalities — particularly acute myeloid leukemia (AML), including TP53-mutant disease. The lead proprietary candidate, ORM-1153, is a CD123-targeting DAC planned for IND submission in H2 2026. Orum also operates a complementary Targeted Protein Stabilization (TPS²) platform, with an initial Cbl-b inhibitor-PD-1 immuno-oncology conjugate program.

The company monetizes through a hybrid, transaction-based model. It licenses its TPD² platform for multi-target use (a July 2024 agreement with Vertex Pharmaceuticals in gene-editing conditioning: $15M upfront, up to $310M per target in option/milestone fees, plus tiered royalties) and divests individual drug programs outright (Bristol Myers Squibb acquired ORM-6151, an anti-CD33 GSPT1 degrader with FDA IND clearance, for $100M upfront plus up to $180M in milestones in November 2023). Orum completed its KOSDAQ IPO in February 2025 (KRX: 475830), raising approximately KRW 50 billion (~US$37M), and subsequently raised an additional ~US$100 million in convertible preferred stock in December 2025 led by KB Investment. The company operates dual headquarters in Daejeon, South Korea and Lexington, Massachusetts, and is led by founder-CEO Sung Joo Lee, Ph.D., with a recently deepened scientific and clinical leadership team.

Customers are exclusively large global pharmaceutical companies; Orum has no approved products and generates no recurring product revenue. The customer base is narrow (BMS, Vertex), making revenue inherently lumpy and event-driven. Recent operational moves — discontinuation of the ORM-5029 HER2 program in April 2025, nomination of ORM-1153 as new lead, AACR 2026 preclinical data presentation, and senior leadership additions — indicate active pipeline focus and preparation for first-in-human clinical execution.

Name

Orum Therapeutics

Legal name

Orum Therapeutics, Inc.

Website

https://orumrx.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Orum Therapeutics is a clinical-stage Korean-American biotech developing degrader-antibody conjugates that combine targeted protein degraders with antibody delivery for oncology, monetizing via pharmaceutical licensing deals and pipeline asset sales.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Targeted protein degradation
• Degrader-antibody conjugates
• Oncology drug development
• Antibody drug conjugates
• Clinical-stage biotechnology

Headquarters

HQ city

Daejeon

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Asset/Program Acquisition: Orum receives upfront payments and milestone payments from pharmaceutical partners acquiring its drug programs. Bristol Myers Squibb acquired the ORM-6151 program for $100M upfront plus potential milestones of $180M total.
2. Platform Licensing and Option Agreements: Orum licenses its TPD² technology platform to pharmaceutical partners for research, development, and commercialization. Vertex partnership includes $15M upfront payment plus up to $310M per target in option fees and milestones plus tiered royalties.
3. Future Product Revenue: Revenue from potential commercialization of proprietary degrader-antibody conjugate pipeline including ORM-1153 for AML and other programs.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Orum Therapeutics is a clinical-stage biotechnology company developing degrader-antibody conjugates (DACs) that combine targeted protein degradation payloads with antibody-based cell-selective delivery for cancer treatment. Its proprietary TPD² (Dual-Precision Targeted Protein Degradation) and TPS² (Dual-Precision Targeted Protein Stabilization) platforms underpin a pipeline led by ORM-1153, a CD123-targeting DAC for acute myeloid leukemia. Orum monetizes its platform and programs primarily through licensing deals and program acquisitions with global pharmaceutical companies.

Product overview

Orum Therapeutics is a clinical-stage biotech pioneering degrader-antibody conjugates (DACs) through its Dual-Precision Targeted Protein Degradation (TPD²) platform and Targeted Protein Stabilization (TPS²) approach. The company's lead pipeline includes ORM-1153 (CD123-targeting GSPT1 degrader for AML, advancing toward IND filing in H2 2026) and earlier-stage programs in solid tumors. Orum has partnered with Vertex for gene editing applications and previously sold its ORM-6151 program to Bristol Myers Squibb. The technology combines proprietary degrader payloads with tumor-targeting antibodies to selectively degrade intracellular proteins via the E3 ubiquitin ligase pathway.

Differentiator

Problem solved

Functional benefit

Products and services

• ORM-1153 A CD123-targeting degrader-antibody conjugate designed to selectively deliver a proprietary GSPT1-degrading payload via a β-glucuronide cleavable linker for treatment of acute myeloid leukemia and other CD123-positive hematological malignancies. Engineered for high internalization efficiency and reduced Fc-gamma receptor interactions.
• TPD² (Dual-Precision Targeted Protein Degradation) Platform Proprietary platform combining targeted protein degrader payloads with antibody-based cell-selective delivery, leveraging the E3 ubiquitin ligase pathway to degrade intracellular target proteins. Licensed to Vertex Pharmaceuticals in July 2024 for development of targeted conditioning agents for gene editing.
• TPS² (Targeted Protein Stabilization) Platform Dual-precision targeted protein stabilization approach using proprietary Cbl-b inhibitor payloads conjugated to antibodies to increase intracellular target protein levels in a cell-type-specific manner for oncology and immuno-oncology applications.
• Cbl-b Inhibitor–PD-1 Conjugate Immuno-oncology preclinical program combining a proprietary Cbl-b inhibitor payload with an anti-PD-1 antibody (pembrolizumab conjugate) to simultaneously block PD-1/PD-L1 signaling and enhance T-cell activation.

Quantifiable outcome

• ORM-1153 demonstrated approximately 1,000-fold higher potency than unconjugated degrader payload in preclinical studies
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Vertex PharmaceuticalscoreStrategic or Co-development Partner · 16 July 2024Global multi-target license and option agreement for Orum's TPD² technology to develop novel DACs for targeted conditioning agents for gene editing. Orum receives $15 million upfront and up to $310 million per target in potential option fees and milestones plus tiered royalties.
• Bristol Myers SquibbcoreStrategic or Co-development Partner · 6 November 2023BMS acquired Orum's ORM-6151 program, a first-in-class anti-CD33 antibody-enabled GSPT1 degrader for AML. Orum received $100 million upfront payment and is eligible for milestone payments totaling up to $180 million. This validates Orum's TPD² platform approach.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Arvinas: Arvinas is the pioneer in targeted protein degradation using PROTACs, with a clinically validated platform. Highly comparable to Orum as both develop degrader-based oncology therapeutics; Arvinas is more mature with partnered programs (with Pfizer, Bayer, Roche/Genentech) analogous to Orum's BMS/Vertex deals.
• Kymera Therapeutics: Kymera develops targeted protein degraders with a focus on immunology and oncology, including partnerships with Vertex and Sanofi. Closely comparable to Orum given shared TPD modality, oncology focus, and partnership-heavy business model.
• C4 Therapeutics: C4 Therapeutics develops small-molecule targeted protein degraders (dTORs/MONODs) for oncology with partnerships including Biogen, Roche, and Calithera. Comparable to Orum as a clinical-stage TPD platform company.
• Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptide-based conjugates (Bicycles) for oncology, partnering with major pharma including Roche, Novartis, and Bayer. Comparable to Orum given shared targeted-conjugate modality and oncology focus; Orum's new board member Dr. Koehler was previously CMO at Bicycle.
• Mersana Therapeutics: Mersana develops next-generation antibody-drug conjugates including Dolasynthen and Immunosynthen platforms. Highly comparable to Orum as an ADC platform company with proprietary linker/payload technology; Orum's Head of Platform Tech joined from Mersana.

Broad incumbents

• ImmunoGen (AbbVie): ImmunoGen pioneered ADCs (Kadcyla, Elahere) and was acquired by AbbVie. Comparable as an established ADC player; broader and more mature than Orum, but represents the commercial endpoint Orum's platform aspires to.
• Daiichi Sankyo: Daiichi Sankyo is a global leader in ADCs (Enhertu, Datroway) partnered with AstraZeneca. Comparable to Orum as an ADC innovator but at much larger scale, representing both a partnership opportunity and a competitive threat.

Emerging players

• Repare Therapeutics: Repare Therapeutics is a precision oncology company developing synthetic lethality-based therapeutics. Comparable to Orum as a clinical-stage oncology biotech of similar size; Orum's new board member Dr. Koehler was previously CMO at Repare.
• Prelude Therapeutics: Prelude Therapeutics develops small molecule targeted protein degraders and other precision oncology candidates. Comparable to Orum as a clinical-stage TPD company; Orum's VP Korea previously held senior roles at Prelude.
• Bolt Biotherapeutics: Bolt Biotherapeutics develops immune-stimulating antibody conjugates (ISACs). Comparable to Orum as a clinical-stage next-generation ADC platform company of similar size and stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/861859943944285
• LinkedInlinkedin.com/company/orum-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds6 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orum Therapeutics